Good morning. Welcome to Axios today. It's Tuesday, November 17th. I'm Naila Boodoo.

Here's how we're making you smarter today. Big Tech's post-election woes.

Plus, the lack of live sports isn't the real reason

cable is dying.

First, though, a vaccine wake-up call

is today's one big thing.

Yesterday the biotech company Moderna announced their coronavirus vaccine was nearly 95% effective at preventing illness.

That's during its preliminary testing. And of course this comes a week after Pfizer

announced a similarly successful vaccine. Axios' health care editor, Sam Baker, is here to give us a reality check on what these

announcements actually mean. Sam, what's the most promising thing to you about yesterday's

announcement from Moderna?

Well, I think there are two things.

The first is the very close to 95% effectiveness rate.

And then for that to be the second vaccine, as you mentioned behind the Pfizer vaccine with 90% or better efficacy.

I mean these are both just press releases so far we'll have to take a closer look at those

numbers but assuming that they hold up,

now we're talking about two really effective products.

Having two of them will mean that we can get more doses of them.

So it's just sort of starting to shape up,

like, yeah, we're really gonna to be able to attack this thing with vaccines.

We also have an exclusive Axios ipso's poll that says 61% of Americans would take a first generation vaccine. I wonder how our

attitude as a country is maybe changing when it comes to thinking about taking a

...